share_log

Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US

Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US

分析师认为CRISPR Treateutics的镰刀细胞候选在美国的时间表有所缓和
Benzinga Real-time News ·  2022/08/09 15:28
  • Barclays says that CRISPR Therapeutics AG's (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the goal of on-track regulatory submissions for CTX001 in SCD/BT by YE22 and CTA submission for VCTX211 (next generation) for Type 1 Diabetes (T1D) in 2H22. 
  • Though investors are focused on BLA submission for CTX001, the analyst expects a high probability of approval even with some delay. 
  • But Barclays has moved to the sidelines, given some questions on the durability of the allogeneic CAR-T programs and the lack of other major data catalysts in the next 12 months. 
  • CRSP is downgraded to Equal Weight with a price target of $88.
  • RBC Capital notes that though SCD/BT filing remains on track for YE-22 in the EU, the Q2 release no longer cites US filing by YE-22, suggesting timing advantage vs. bluebird bio Inc (NASDAQ:BLUE) (still guiding 1Q23 filing) may have narrowed. 
  • Overall, RBC struggles with the commercial case for SCD and read Pfizer Inc's (NYSE:PFE) buyout of Global Blood Therapeutics Inc (NASDAQ:GBT) as indirect evidence that gene therapy/editing is unlikely to disrupt the market in the foreseeable future materially.
  • RBC has lowered the price target from $85 to $78, reiterating the Sector Perform rating.
  • Price Action: CRSP shares are down 6.32% at $76.25 during the market session on the last check Tuesday.
  • 巴克莱这么说的CRISPR治疗股份公司纳斯达克(新浪纳斯达克股票代码：CRSP)22财年第二季度收益报告基本上是递增的，突出了多个临床项目的进展，包括22年前提交SCD/BT中CTX001的在轨监管报告以及22年下半年提交1型糖尿病(T1D)VCTX211(下一代)的CTA报告的目标。
  • 尽管投资者关注的是CTX001的BLA提交，但分析师预计，即使有一些延迟，批准的可能性也很高。
  • 但鉴于同种异体CAR-T计划的持久性以及未来12个月缺乏其他主要数据催化剂的问题，巴克莱已经采取了观望态度。
  • CRSP评级下调至持平，目标价为88美元。
  • 加拿大皇家银行资本指出，尽管SCD/BT申请仍在欧盟的YE-22的轨道上，但第二季度的新闻稿不再引用YE-22在美国的申请，这表明相对于蓝鸟生物公司(纳斯达克：BLUE)(仍在指导1Q23申请)的时机优势可能已经缩小。
  • 总体而言，加拿大皇家银行在SCD和Read的商业案例中举步维艰辉瑞(纽约证券交易所股票代码：PFE)收购全球血液治疗公司(纳斯达克：GBT)作为基因治疗/编辑在可预见的未来不太可能实质性扰乱市场的间接证据。
  • 加拿大皇家银行已将目标价从85美元下调至78美元，重申了行业表现评级。
  • 价格行动：CRSP股价周二尾盘下跌6.32%，至76.25美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发